- Home
- SNTI vs KAPA Comparison
SNTI vs KAPA Comparison
Compare SNTI & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- KAPA
- Stock Information
- Founded
- SNTI 2016
- KAPA 2013
- Country
- SNTI United States
- KAPA United States
- Employees
- SNTI N/A
- KAPA N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- KAPA
- Sector
- SNTI Health Care
- KAPA
- Exchange
- SNTI Nasdaq
- KAPA NYSE
- Market Cap
- SNTI 21.3M
- KAPA 18.8M
- IPO Year
- SNTI N/A
- KAPA 2024
- Fundamental
- Price
- SNTI $3.96
- KAPA $1.27
- Analyst Decision
- SNTI Strong Buy
- KAPA Strong Buy
- Analyst Count
- SNTI 1
- KAPA 1
- Target Price
- SNTI $12.00
- KAPA $9.00
- AVG Volume (30 Days)
- SNTI 30.3K
- KAPA 969.6K
- Earning Date
- SNTI 03-20-2025
- KAPA 03-04-2025
- Dividend Yield
- SNTI N/A
- KAPA N/A
- EPS Growth
- SNTI N/A
- KAPA N/A
- EPS
- SNTI N/A
- KAPA N/A
- Revenue
- SNTI N/A
- KAPA N/A
- Revenue This Year
- SNTI $11.52
- KAPA N/A
- Revenue Next Year
- SNTI $78.57
- KAPA N/A
- P/E Ratio
- SNTI N/A
- KAPA N/A
- Revenue Growth
- SNTI N/A
- KAPA N/A
- 52 Week Low
- SNTI $1.52
- KAPA $0.85
- 52 Week High
- SNTI $16.94
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- SNTI 45.36
- KAPA N/A
- Support Level
- SNTI $3.92
- KAPA N/A
- Resistance Level
- SNTI $4.50
- KAPA N/A
- Average True Range (ATR)
- SNTI 0.26
- KAPA 0.00
- MACD
- SNTI -0.03
- KAPA 0.00
- Stochastic Oscillator
- SNTI 20.59
- KAPA 0.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.